← Oncology Approval Tracker

FDA DECISION ·

Degevma

denosumab-adet · Teva Pharmaceuticals

Biosimilar approvalBiosimilarCancer-related bone complications
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Xgeva biosimilar to prevent skeletal-related events in multiple myeloma or solid tumor bone metastases, treat certain unresectable or high-morbidity giant cell tumors of bone, and treat hypercalcemia of malignancy refractory to bisphosphonates.

LAMPGEN ANALYSIS

Why it matters

The decision adds a biosimilar across tumor-related bone uses. The Xgeva-referenced presentation and its indications differ from the Prolia-referenced formulation.

What research teams should watch

Match the product and indication in pharmacy records. Monitor product availability and keep calcium and dental safety workflows visible.

PRIMARY RECORDS

Sources